Brexpiprazole Tablet
Product Images NDC 27241-207

Product Visual Gallery

This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Brexpiprazole (NDC 27241-207). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Ajanta Pharma Usa Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

0.25mg (Brexpiprazole 0 25mg)

This medication contains 0.25 mg of brexpiprazole per film-coated tablet. The recommended dosage should be obtained from the package insert. The tablets should be stored at a temperature between 20°C to 25°C, with excursions allowed between 15°C to 30°C. This medication is child-resistant. Dispensers should provide the medication alongside the accompanying guide to each patient. This medication is marketed and distributed by Ajanta Pharma USA Inc, in Bridgewater, NJ. It is manufactured in India.*

FDA Label Image

0.5mg (Brexpiprazole 0 5mg)

Brexpiprazole tablets are a prescription medication containing 0.5 mg of brexpiprazole. The accompanying package insert should be consulted for information on indications and dosages. These tablets should be kept out of reach of children, and the package is child-resistant. The tablets should be stored between 20°C to 25°C (68°F to 77°F) with limited excursions between 15°C to 30°C (59°F to 86°F). The medication is marketed by Ajanta Pharma USA Inc. and made in India. The NDC (National Drug Code) for this product is 27241-205-30, and each package contains 30 tablets.*

FDA Label Image

1mg (Brexpiprazole 1mg)

Each film-coated tablet contains 1 mg of brexpiprazole. Please refer to the accompanying package insert for indications and dosage information. Brexpiprazole tablets should be kept at 20°C to 25°C (68°F to 77°F). They can be stored between 15°C to 30°C (59°F to 86°F) with excursions permitted [see USP Controlled Room Temperature]. This package is child-resistant, and brexpiprazole tablets should be kept out of reach of children. The medication is made in India and marketed by Ajanta Pharma USA Inc. Each pack contains 30 tablets. The code no. is GUJ/IDRUGS/G/25/2080.*

FDA Label Image

2mg (Brexpiprazole 2mg)

Each tablet of this medication contains 2mg of brexpiprazole. The recommended usual dosage is specified in the package insert. These tablets are child-resistant and must be kept out of reach of children. They should be stored between 20°C to 25°C (68°F to 77°F), with excursions allowed between 15°C to 30°C (59°F to 86°F). The manufacturer is Ajanta Pharma USA Inc. and the product is made in India. It comes in a package containing 30 tablets and is marked with NDC 27241-207-30. Pharmacists are advised to dispense the accompanying medication guide to each patient. The code number is GUJ/IDRUGS/G/25/2080, and the product identification number is 3017647.*

FDA Label Image

3mg (Brexpiprazole 3mg)

Each film-coated tablet contains 3 mg of brexpiprazole. Please refer to the accompanying package insert for dosage and indications. The medication should be stored at 20°C to 25°C (68°F to 77°F) and is child-resistant. Brexpiprazole is marketed by Ajanta Pharma USA Inc. and is made in India. The NDC code is 27241-208-30 and there are 30 tablets in each package. This text is a medication guide for pharmacists and patients.*

FDA Label Image

4mg (Brexpiprazole 4mg)

Each tablet of this medication contains 4 mg of brexpiprazole. The package insert should be consulted for dosage and indication information. These tablets should be kept out of the reach of children and stored at a temperature of 20°C to 25°C (68°F to 77°F). This medication is manufactured by Ajanta Pharma in India and distributed by Ajanta Pharma USA Inc. The package contains 30 tablets and is labeled with product and code numbers.*

FDA Label Image

Figure1 (Brexpiprazole Figure1)

Brexpiprazole PK data is available on measures of fold change and 90% confidence intervals for different categories such as renal and hepatic impairment, gender, and age. The population description is also provided. However, the actual values and details are not clear from the text obtained through .*

FDA Label Image

Figure2 (Brexpiprazole Figure2)

The text provides information on the effects of certain drugs on Brexpiprazole PK. The drugs include CYP3A4 inhibitor Ketoconazole, CYP2D6 inhibitor Quinidine, CYP3A4 inducer Rifampin, CYP2B6 inhibitor Ticlopidine, and gastric PH increase Omeprazole. The text provides a table with Fold Change and 90% confidence intervals for various measures such as Cmax and AUCinf. The table shows the changes in Brexpiprazole PK relative to the reference without interacting drugs.*

FDA Label Image

Figure3 (Brexpiprazole Figure3)

FDA Label Image

Figure4 (Brexpiprazole Figure4)

FDA Label Image

Figure5 (Brexpiprazole Figure5)

FDA Label Image

Figure6 (Brexpiprazole Figure6)

FDA Label Image

Structure (Brexpiprazole Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.